Is VK2735 available for purchase?

No. VK2735 is in Phase 3 clinical development by Viking Therapeutics and is only available through clinical trials. Its proprietary sequence is not available from research chemical vendors.

How does VK2735 compare to tirzepatide?

Both are dual GLP-1/GIP receptor agonists. VK2735 showed 14.7% weight loss in just 13 weeks (Phase 2), which is a faster rate than tirzepatide demonstrated at similar timepoints. However, the Phase 2 trial was short and small. The Phase 3 VANQUISH trial will provide longer-term data for more meaningful comparison. Viking Therapeutics is a smaller company than Eli Lilly.

Why is VK2735 discussed on stock forums?

Viking Therapeutics (VKTX) is a publicly traded biotech company. VK2735 is their lead asset, and clinical data releases cause significant stock price movements. As a result, VK2735 discussion often occurs on investment subreddits (r/stocks, r/wallstreetbets) in addition to peptide communities.

Will VK2735 be available in both injectable and oral forms?

Viking Therapeutics is developing both formulations simultaneously. The subcutaneous injectable showed 14.7% weight loss at 13 weeks, while the oral version showed 12.2% at 13 weeks. Phase 3 VANQUISH trials are underway for the injectable version. If both are ultimately approved, patients would have the choice between weekly injection and daily oral dosing.

VK2735: Community Protocols & Reports

Aggregated community experiences, protocols, and stacking patterns

Anecdotal Reports0

Community-Sourced Information

The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.

For peer-reviewed dosing protocols, see the clinical dosing guide.

Browse community protocols for all 130 peptides →

✓Reviewed byEditorial Team

📅Updated February 16, 2026

Unverified

📌TL;DR

•Community protocols detailed below
•Evidence level: Anecdotal Reports
•See community reports below
•Stacking patterns detailed below

Clinical vs. Community Protocol Differences

How community-reported protocols differ from clinical research protocols.

Aspect	Clinical Approach	Community Approach	Significance
Availability	VK2735 is in Phase 3 development by Viking Therapeutics. Both injectable and oral formulations are being developed. The Phase 3 VANQUISH trial has enrolled over 4,500 patients.	No established community access exists. VK2735's proprietary sequence is not available from research chemical vendors. Community discussion is primarily stock-market driven due to Viking Therapeutics being a publicly traded biotech (VKTX).	high Community interest in VK2735 is uniquely intertwined with investor interest in Viking Therapeutics stock, which has experienced significant volatility around clinical data releases.
Dual Formulation Development	Viking is developing both subcutaneous (once weekly) and oral (once daily) formulations simultaneously, a strategy that may accelerate market entry with dual options.	The community values the dual formulation approach. The oral version showing 12.2% weight loss at 13 weeks is seen as potentially competitive with orforglipron while maintaining the option of a more potent injectable version.	moderate The injectable formulation showed 14.7% weight loss in 13 weeks, suggesting greater weight loss potential than the oral version, following the pattern seen with other GLP-1 agents.

Compare these community approaches with published research findings.

Sources

Reddit r/Peptides|VK2735 and Viking Therapeutics pipeline discussions(accessed 2026-02-16)
Reddit r/Semaglutide|Next-generation dual agonist pipeline including VK2735(accessed 2026-02-16)
Reddit r/stocks|Viking Therapeutics (VKTX) VK2735 clinical data discussions(accessed 2026-02-16)

Community Evidence Overview#

This page presents aggregated community protocols and anecdotal reports for VK2735. The information below is gathered from Reddit communities and online forums. This is not clinical evidence and should not be used as medical guidance.

VK2735 has generated significant community and investor interest based on its rapid Phase 2 weight loss data and dual formulation development strategy. No community use exists outside clinical trials.

Phase 3 Development#

VK2735 is in Phase 3 clinical development by Viking Therapeutics (VANQUISH trials), with over 4,500 patients enrolled. Both injectable and oral formulations are being developed simultaneously.

Community and Investor Overlap#

VK2735 community discussion is unique among obesity peptides in that it frequently occurs on investment-focused forums alongside peptide communities. Viking Therapeutics (VKTX) is a publicly traded biotech, and VK2735 clinical data releases have been significant market-moving events.

Community Interest Drivers#

Rapid weight loss: 14.7% in just 13 weeks (injectable), suggesting potential for greater long-term efficacy
Oral formulation: 12.2% weight loss in 13 weeks with once-daily oral dosing
Dual formulation strategy: Both injectable and oral options being developed
No plateau observed: Similar to CT-388, weight loss curves showed no sign of plateauing in the short Phase 2 trial
Smaller biotech: Some community members see potential for Viking to be acquired by larger pharma, driving investor interest

Important Caveats#

Phase 2 data from short 13-week trials; Phase 3 results pending
Not available outside clinical trials
Proprietary compound that cannot be synthesized externally
No community use data exists
Stock price discussions may create biased community narratives
Smaller biotech company faces development and commercialization challenges

Subscribe to see vendor options

Free access to verified vendor scores, pricing, and suppliers.

150+ peptide profiles · 30+ comparisons · 18 research tools

Already subscribed?

Frequently Asked Questions About VK2735

Explore Further

Calculate your dose

Reconstitution volumes, injection doses, and supply planning

⚠️

Medical Disclaimer

This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.

Compare Tools Vendors